Precision cancer medicine, the use of genomic profiling of patient tumors at the point-of-care to inform treatment decisions, is rapidly changing treatment strategies across cancer types. Precision medicine for advanced prostate cancer may identify new treatment strategies and change clinical practice. In this review, we discuss the potential and challenges of precision medicine in advanced prostate cancer.
INTRODUCTION
Precision cancer medicine, the use of genomic profiling at the point-of-care to inform treatment decisions ( Fig. 1) , is changing cancer care by enabling more accurate and efficient prediction of therapies for individual cancer patients. This revolution is the result of numerous studies identifying key cancer drivers, their alterations, and therapies to specifically target these alterations [1] . More recently, multiple cancer landscape studies have provided further insight into the alterations within and between tumor types [2] . That success, along with the increased affordability and reliability of sequencing, and development of computational tools for clinical genomic analysis, has led to the integration of genome science directly into clinical practice. Tight networks and collaboration between clinicians, genome scientists, and pharmaceuticals companies will continue to advance precision medicine [3] [4] [5] .
Prostate cancer is the most common solid tumor in men in the USA [6] . Prostate cancer is a hormonedependent tumor, demonstrated by recurrent alterations in the androgen receptor and its pathway [7] . Castration-resistant prostate cancer (CRPC) is a lethal clinical state in which the tumor has developed resistance to androgen deprivation therapy. This occurs in the majority of advanced or metastatic prostate cancer patients. The genomic landscape of localized prostate cancer has been well defined [8] [9] [10] [11] 12 && , [13] [14] [15] . Multiple studies have highlighted the lack of highly recurrent clinically actionable alterations, as well as the high level of tumor intraheterogeneity even in the primary setting [15, 16] . In contrast with the primary prostate cancer genome, the extensive mutational landscape of metastatic CRPC lesions has exposed the possibility of targeted therapies and precision medicine in CRPC [17 && ]. In this review, we discuss the potential of genomics to impact the clinical management of
CURRENT THERAPEUTIC APPROACHES FOR CASTRATION-RESISTANT PROSTATE CANCER
In the CRPC setting, the primary successful therapeutic target remains the androgen receptor. The discovery of androgen receptor, along with the persistent unearthing of androgen receptor resistance mechanisms, has enabled additional effective treatments in CRPC patients [7, [18] [19] [20] [21] . Approved therapies in this space include new androgen synthesis pathway agents, such as abiraterone, and direct inhibitors of androgen receptor, such as enzalutamide [22] [23] [24] [25] [26] [27] [28] . However, the majority of CRPC patients ultimately develop resistance to androgen receptor-focused therapies, despite multiple new agents reaching the clinic. Furthermore, there are many patients who never respond to these therapies and manifest intrinsic resistance to this therapeutic approach. Generally, almost all patients with CRPC ultimately succumb to the disease.
Genomics and lethal prostate cancer
Studies examining the genomic alterations involved in lethal prostate cancer from autopsy cohorts revealed the underlying biology behind the disease and the evolutionary processes driving advanced disease [29,30 && ,31,32 && ]. Despite these crucial insights, these studies did not have clinical cohorts to explore the landscape of potential clinically actionable targets. Recently, a study examined 150 metastatic site biopsies from living patients with CRPC through integrative whole-exome sequencing (WES) and whole transcriptome sequencing [17 && ]. A high number of targetable mutations, defined as predicting response or resistance to a therapy, or
KEY POINTS
Precision medicine shows great promise in advanced prostate cancer, but it is still in the initial stages.
Advancement in prostate cancer precision medicine is dependent on continuous research in prostate cancer genomics and correlation with response to current and novel therapies.
Expansion of liquid biopsy techniques, such as circulating tumor cells or cell-free DNA, may be especially impactful in precision medicine for CRPC. FIGURE 1. Precision medicine in advanced prostate cancer revolves around the ability to take a tumor sample, ideally metastatic tumor, sequence the tumor, and assign therapy to the patient. This involves biopsy of tumor tissue, DNA/RNA extraction, WES/WGS/Transcriptome sequencing, bioinformatics interpretation of results, and assignment of treatment based on therapeutic profile. This process may be repeated as needed when patients progress. WES, whole-exome sequencing; WGS, whole genome sequencing.
having a diagnostic or prognostic utility, were found in these patients, in contrast to localized prostate cancer. Not including androgen receptor, 65% of patients had a targetable mutation, many of which have been linked to ongoing clinical trials ( Table 1 ). The details of these findings are described below.
Androgen receptor
Numerous studies have addressed the androgen receptor and its pathway alterations in metastatic CRPC [7, 29, 30 && ,31,32 && ]. Despite reduced androgen circulation in CRPC, androgen receptor is still activated through various mechanisms, including androgen receptor amplification or overexpression, activating androgen receptor mutations, alterative androgen production, androgen receptor coactivator overexpression, and indirect androgen receptor activation [33] . Robinson et al. presented that 34% of CRPC patients still have only androgen receptor as a clinically relevant mutation, indicating they may be differentially sensitive to existing and novel androgen receptor-directed therapies. However, the clinical significance of these androgen receptor mutations for predicting response or resistance to these agents remains to be determined. Although several drugs have shown promise targeting androgen receptor in this space, including abiraterone and enzalutamide, most patients eventually develop resistance to these agents [23, 25, 26] . Recently, it was reported that patients with androgen receptor-V7 splice variant, in the transcriptomic data, may be resistant to enzalutamide but respond to galeterone, a novel androgen receptor therapy currently in phase III trials [34 & ,35] , potentially demonstrating the first genomically driven therapy in CRPC. Furthermore, there are numerous experimental agents that target androgen receptor or its pathway in novel ways (Table 1) that may augment the ability to effectively inhibit this dominant pathway in patients with tumors that are still wholly dependent on androgen receptor signaling.
DNA repair pathway
Beyond the androgen receptor pathway, the most striking result from clinical genomic profiling of CRPC patients was that 19% of patients have a DNA repair pathway alterations, including 12.7% of patients with a putative pathogenic BRCA2 germ line mutation [36, 37] . Additional somatic and germ line DNA repair alterations were found in ATM, BRCA1, CDK12, FANCA, RAD51B, and RAD51C.
Many of these alterations are associated with platinum response in other cancer types [38] [39] [40] . 
Phosphoinositide 3-kinase pathway
The phosphoinositide 3-kinase (PI3K) pathway is recurrently mutated in CRPC, commonly through loss of PTEN, amplification of PIK3CA/B, and activating mutation of PIK3CA/B and AKT1 [42] . In Robinson et al., PI3K pathway was altered in 49% of patients, making it the second most frequently altered pathway after androgen receptor. In the past, many PI3K monotherapies have had a lack of efficacy, thought to be because of lack of specificity, coexisiting alterations, and signaling feedback [43 & ]. Recently, multiple inhibitors of specific PI3K isoforms have begun testing in clinical trials, potentially increasing the specificity of these agents. In CRPC, there are recurrent mutations in PIK3CB and frequent loss of PTEN, which may activate PIK3CB over PIK3CA [44] , emphasizing the need for these specific PI3K isoforms inhibitors [45, 46] to effectively clinically target this pathway. There has also been evidence that there is cross-pathway interaction between PI3K and homologous recombination pathway, indicating that patients with PI3K pathway alterations may respond to PARP inhibitors as well [47] [48] [49] .
WNT pathway
In Robinson et al., 18% of metastatic CRPC patient are presented with mutation in WNT pathway, including activating CTNNB1, APC, RNF43, RSPO2, and ZNRF3 mutations. Furthermore, a recent study of CRPC patients' circulating tumor cells demonstrated an upregulation of WNT signaling in this clinical setting [50] . Historically, the WNT pathway has been extremely difficult to target because of the multitude of receptors, ligands, and downstream pathways [51] . The WNT pathway has many imperative biologic functions from embryonic development to tissue homeostasis and is activated by proteins secreted by tumor cells as part of an autocrine loop, or they may be produced by surrounding stromal cells, increasing the difficulty of targeting this pathway. The WNT pathway is also thought to be activated in cancer stem cells, which are thought to drive resistance to many therapies [52 & ]. Although it is known that the WNT signaling pathway is altered in CRPC, it is unknown whether an antagonist or agonist would work better to inhibit growth. There is contradicting evidence in multiple tumor types whether activation or repression of the pathway increases survival. Evidence also supports b-catenin signaling in dictating tissue-specific predisposition to APC-driven tumorigenesis [53] , helping to indicate whether a repressor or activator would work best. This is again demonstrated by the contradicting therapeutics currently in clinical trials (Table 1) : Foxy-5 activates the WNT pathway, whereas OMP-54F28 inhibits the pathway. Efficacy data will inform their utility in this clinical setting. Additional preclinical and clinical studies are needed to determine how to best target this pathway in CRPC. It is also known that all of the WNT pathway therapeutics have had significant toxicities associated because of the wide range of functions of the WNT pathway [54] .
Cell cycle pathway
Loss of RB1 was seen in 21% of metastatic biopsies versus 1% in localized prostate cancer [15,17 && ]. Less common cell cycle pathway alterations including mutations in CDKN2A/B, CDKN1B, and amplifications of CCND1, were seen. The major role of the cell cycle pathway is to stop mitosis to allow for DNA repair via the inhibition of cyclin-dependent kinases (CDKs) and RB1 phosphorylation [55] . CDK4/6 inhibition can induce cell cycle arrest and cancer cell senescence. Currently, there is one CDK4/6 inhibitor approved in breast cancer, and multiple other CDK4/ 6 and pan-CDK inhibitors in clinical trials [56] . In CRPC, there are multiple trials for CDK4/6 inhibitors (Table 1 ). There are known resistance to these drugs, including Rb-negativity and a lack of codeletion of CDKN2A/CDKN2B in glioblastoma, indicating any trial with these compounds must be genomically driven and may be relevant in CRPC [57] .
Immunotherapy
The most mature effort for CRPC immunotherapy is sipuleucel-T, a cell-based immunotherapy, which is Federal Drug Administration approved [22] . It is created using mature, autologous antigen-presenting cells obtained from patients. However, this approach has thus far not resulted in clinical benefit in stratified patient subsets. In order to expand immunotherapy approaches in the setting of success in other tumor types, multiple checkpoint inhibitors have been testing in CRPC, although thus far, these therapies have had limited clinical results [58] . Notably, multiple studies have recently demonstrated a correlation between response to immune checkpoint inhibitors and mutational burden [59 && -61 && ]. A subset of CRPC patients has a high mutation load because of alterations in mismatch repair genes, MLH1 and MSH2. Thus, CRPC patients with a high mutational burden may benefit greatly from immunotherapy, such as a checkpoint inhibitor, and future efforts geared toward determining whether this relationship holds across CRPC patients may inform the clinical utility of checkpoint inhibitors in the CRPC setting.
TECHNOLOGIES FOR ENHANCING PRECISION MEDICINE IN CASTRATION-RESISTANT PROSTATE CANCER
Despite continuous advances in high-throughput genomic sequencing technologies and their utilization in cancer, there are several challenges in successful implementation of precision medicine in CRPC (Table 2) . For example, access to tumor tissue for profiling is especially complicated because of the need to obtain metastatic biopsies, including bone metastasis [62] and the low percentage of cancer cells in many of these samples. Although it has been demonstrated that sequencing tumor from bone biopsies is feasible, these approaches are difficult and require much expertise [63 & ]. There is also the reality that not all patients can get a biopsy or that the capacity of interventional radiology facilities will permit biopsy sampling in all patients. Moreover, a single biopsy may not capture the extent of disease. As demonstrated in localized prostate cancer and by studying multiple metastatic sites from individual patients, there is significant intratumor heterogeneity in prostate cancer [30
&&
]. If a patient has multiple metastatic sites, only sampling one, may not demonstrate the biology of the whole tumor. In addition, one must also consider the possibility of not finding any targetable genetic alteration in a patient's tumor. With additional genomics research and novel therapeutics, this possibility will decrease.
A potential technology that may address difficulty in obtaining biopsies, and tumor heterogeneity in CRPC is the use of liquid biopsy techniques. One such approach involves the use of circulating tumor cells (CTCs) to identify genomic alterations of CRPC. CTCs have been demonstrated to have a reasonable readout of the tumor genomic landscape in patients with CRPC [64] . Circulating tumor DNA (ctDNA) is another novel way to identify genomic alterations and track patient's genomic landscape over time [65 & ]. In other tumor types, WES has been performed from ctDNA [66 && ], indicating metastatic biopsies may not be needed in the future. These technologies may also help us identify patients who are developing resistance earlier than a radiological scan [64, 67, 68] . As seen in multiple other cancer types, the genomic profile of tumors after treatment is often very differ- 
CLINICAL STRATEGIES TO IMPLEMENT PRECISION MEDICINE
A major logistical challenge toward implementing precision medicine in CRPC and across cancer types is building an infrastructure for genomic sequencing in cancer, including collecting tissue, genomic alterations testing, genomic analysis, and reporting results back to patients [72 && ,73 && ,74-77]. Another limitation to genomic sequencing is cost. Although the cost of genomic sequencing is continuously decreasing, it is rarely covered by insurance [78] , causing limited access to many patients [79] . In addition, once genomic alterations are identified, it is often difficult for patients to get access to affordable medication [80] . Finally, owing to the small percentage of patients with particular genomic alterations, new clinical trial schemas have been developed to support ongoing precision medicine therapeutics.
Two efficient ways to test the effects of multiple drugs is through a basket or umbrella trial ( Fig. 2a and b) . These trial schemas have been well demonstrated in lung cancer [81] and are currently a declared initiative of the National Institutes of Health (NIH). The National Cancer Institute program, a large basket trial initiative, will include 3000 patients with different types of cancer to find early signals of a response to targeted therapies. Basket trials test the effect of a single drug targeting a specific molecular alteration in a variety of cancers. This design not only allows for a faster identification of candidate patient, but also to assess the potential value of this targeted therapy across different tumor types. An umbrella trial assesses the effect of different drugs in different molecular alterations either in one or several tumors. This would involve sequencing the tumors of all men with CRPC, and placed in the appropriate slot based on the genomic profile. One additional challenge to umbrella trials is identifying the correct driver mutation. Ongoing efforts to identify and rank known driver mutations [72 && ] should help place patients in the appropriate slot. These trial schemas will also help drug development for less common alterations. Implementing either of these trial schemas for CRPC will allow expedited identification of targeted therapies that work well in this setting.
CONCLUSION
The concept of precision medicine driven by genomics for CRPC is appealing; however, it is in its infancy. We must continue to obtain additional genomic information and correlate this with therapeutic response. Developing catalogues of CRPC cancer-related genes, together assessments of pathway activation could enable a better identification of additional driver in the future. The characterization of the genomic landscape of tumors and of the activated protein network will guide combination therapies to optimize therapeutic effects. Finally, logistics and operational challenges need to be addressed. The article presents evidence for polyclonal seeding in androgen-deprived metastatic prostate cancer. Whole genome sequencing from multiple metastatic sites from 10 patients identified evolution from primary tumors and multiple metastatic sites. Metastasis-to-metastasis spread was found to be common as well as de novo monoclonal seeding in metastatic sites. 33. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009; 15:4792-4798. 34.
